Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors

Annelies Verbiest; Inne Renders; Stefano Caruso; Gabrielle Couchy; Sylvie Job; Annouschka Laenen; Virginie Verkarre; Nathalie Rioux-Leclercq; Patrick Schöffski; Yann Vano; Reza Thierry Elaidi; Evelyne Lerut; Maarten Albersen; Stéphane Oudard; Wolf Hervé Fridman; Catherine Sautès-Fridman; Laurence Albigès; Agnieszka Wozniak; Jessica Zucman-Rossi; Benoit Beuselinck

doi:10.1016/j.clgc.2019.05.009

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors

Annelies Verbiest, Inne Renders, Stefano Caruso, Gabrielle Couchy, Sylvie Job, Annouschka Laenen, Virginie Verkarre, Nathalie Rioux-Leclercq, Patrick Schöffski, Yann Vano, Reza Thierry Elaidi, Evelyne Lerut, Maarten Albersen, Stéphane Oudard, Wolf Hervé Fridman, Catherine Sautès-Fridman, Laurence Albigès, Agnieszka Wozniak, Jessica Zucman-Rossi, Benoit Beuselinck

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

33 Citations (Scopus)

Résumé

In advanced clear-cell renal cell carcinoma, the Checkmate214 study showed superior outcomes with ipilimumab-nivolumab in International Metastatic RCC Database Consortium intermediate-/poor-risk patients and with sunitinib in good-risk patients. We demonstrate how underlying molecular subtypes and angiogenic gene expression can explain these differences and can characterize the heterogeneous International Metastatic RCC Database Consortium intermediate-risk group.

langue originale	Anglais
Pages (de - à)	e981-e994
journal	Clinical Genitourinary Cancer
Volume	17
Numéro de publication	5
Les DOIs	https://doi.org/10.1016/j.clgc.2019.05.009
état	Publié - 1 oct. 2019

Accès au document

10.1016/j.clgc.2019.05.009

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Verbiest, A., Renders, I., Caruso, S., Couchy, G., Job, S., Laenen, A., Verkarre, V., Rioux-Leclercq, N., Schöffski, P., Vano, Y., Elaidi, R. T., Lerut, E., Albersen, M., Oudard, S., Fridman, W. H., Sautès-Fridman, C., Albigès, L., Wozniak, A., Zucman-Rossi, J., & Beuselinck, B. (2019). Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 17(5), e981-e994. https://doi.org/10.1016/j.clgc.2019.05.009

@article{b3b2de29af164f35b99f8b62a36da0dc,

title = "Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors",

abstract = "In advanced clear-cell renal cell carcinoma, the Checkmate214 study showed superior outcomes with ipilimumab-nivolumab in International Metastatic RCC Database Consortium intermediate-/poor-risk patients and with sunitinib in good-risk patients. We demonstrate how underlying molecular subtypes and angiogenic gene expression can explain these differences and can characterize the heterogeneous International Metastatic RCC Database Consortium intermediate-risk group.",

keywords = "Angiogenesis, Biomarker, Immune checkpoint inhibitor, Molecular subtype, Sunitinib",

author = "Annelies Verbiest and Inne Renders and Stefano Caruso and Gabrielle Couchy and Sylvie Job and Annouschka Laenen and Virginie Verkarre and Nathalie Rioux-Leclercq and Patrick Sch{\"o}ffski and Yann Vano and Elaidi, {Reza Thierry} and Evelyne Lerut and Maarten Albersen and St{\'e}phane Oudard and Fridman, {Wolf Herv{\'e}} and Catherine Saut{\`e}s-Fridman and Laurence Albig{\`e}s and Agnieszka Wozniak and Jessica Zucman-Rossi and Benoit Beuselinck",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = oct,

day = "1",

doi = "10.1016/j.clgc.2019.05.009",

language = "English",

volume = "17",

pages = "e981--e994",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

number = "5",

}

Verbiest, A, Renders, I, Caruso, S, Couchy, G, Job, S, Laenen, A, Verkarre, V, Rioux-Leclercq, N, Schöffski, P, Vano, Y, Elaidi, RT, Lerut, E, Albersen, M, Oudard, S, Fridman, WH, Sautès-Fridman, C, Albigès, L, Wozniak, A, Zucman-Rossi, J & Beuselinck, B 2019, 'Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors', Clinical Genitourinary Cancer, VOL. 17, Numéro 5, p. e981-e994. https://doi.org/10.1016/j.clgc.2019.05.009

TY - JOUR

T1 - Clear-cell Renal Cell Carcinoma

T2 - Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors

AU - Verbiest, Annelies

AU - Renders, Inne

AU - Caruso, Stefano

AU - Couchy, Gabrielle

AU - Job, Sylvie

AU - Laenen, Annouschka

AU - Verkarre, Virginie

AU - Rioux-Leclercq, Nathalie

AU - Schöffski, Patrick

AU - Vano, Yann

AU - Elaidi, Reza Thierry

AU - Lerut, Evelyne

AU - Albersen, Maarten

AU - Oudard, Stéphane

AU - Fridman, Wolf Hervé

AU - Sautès-Fridman, Catherine

AU - Albigès, Laurence

AU - Wozniak, Agnieszka

AU - Zucman-Rossi, Jessica

AU - Beuselinck, Benoit

PY - 2019/10/1

Y1 - 2019/10/1

N2 - In advanced clear-cell renal cell carcinoma, the Checkmate214 study showed superior outcomes with ipilimumab-nivolumab in International Metastatic RCC Database Consortium intermediate-/poor-risk patients and with sunitinib in good-risk patients. We demonstrate how underlying molecular subtypes and angiogenic gene expression can explain these differences and can characterize the heterogeneous International Metastatic RCC Database Consortium intermediate-risk group.

AB - In advanced clear-cell renal cell carcinoma, the Checkmate214 study showed superior outcomes with ipilimumab-nivolumab in International Metastatic RCC Database Consortium intermediate-/poor-risk patients and with sunitinib in good-risk patients. We demonstrate how underlying molecular subtypes and angiogenic gene expression can explain these differences and can characterize the heterogeneous International Metastatic RCC Database Consortium intermediate-risk group.

KW - Angiogenesis

KW - Biomarker

KW - Immune checkpoint inhibitor

KW - Molecular subtype

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=85067352180&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2019.05.009

DO - 10.1016/j.clgc.2019.05.009

M3 - Article

C2 - 31229459

AN - SCOPUS:85067352180

SN - 1558-7673

VL - 17

SP - e981-e994

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 5

ER -